A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

被引：2

作者：

Christofyllakis, Konstantinos ^{[1
]}

Poeschel, Viola ^{[1
]}

Altmann, Bettina ^{[2
]}

Maurer, Stephanie ^{[1
]}

Lesan, Vadim ^{[1
]}

Bittenbring, Joerg ^{[1
]}

Kos, Igor Age ^{[1
]}

Kaddu-Mulindwa, Dominic ^{[1
]}

Abdi, Zanir ^{[1
]}

Fleser, Octavian ^{[1
]}

Altmeyer, Sarah ^{[1
]}

Neuendorff, Nina Rosa ^{[3
]}

Nickelsen, Maike ^{[4
]}

Held, Gerhard ^{[5
]}

Dreyling, Martin ^{[6
]}

Zettl, Florian ^{[7
]}

Buske, Christian ^{[8
]}

Lenz, Georg ^{[9
]}

Glass, Bertram ^{[10
]}

Chapuy, Bjoern ^{[11
]}

Schmitz, Norbert ^{[9
]}

Vassilakopoulos, Theodoros ^{[12
]}

Ott, German ^{[13
,14
]}

Siebert, Reiner ^{[15
,16
]}

Viardot, Andreas ^{[15
,16
]}

Scherer, Florian ^{[17
]}

Schmitz, Roland ^{[18
]}

Rosenwald, Andreas ^{[19
]}

Hellwig, Dirk ^{[20
]}

Loeffler, Markus ^{[2
]}

Stilgenbauer, Stephan ^{[21
]}

Thurner, Lorenz ^{[1
]}

Bewarder, Moritz ^{[1
]}

Ziepert, Marita ^{[2
]}

机构：

[1] Saarland Univ, Med Ctr, Dept Internal Med Oncol Hematol Clin Immunol & Rh, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany

[3] Univ Hosp Essen, Dept Haematol & Stem Cell Transplantat, Essen, Germany

[4] Onkol Lerchenfeld, Hamburg, Germany

[5] Westpfalz Klinikum, Dept Internal Med 1, Kaiserslautern, Germany

[6] LMU Univ Hosp, Dept Internal Med 3, Munich, Germany

[7] Klinikum Traunstein, Dept Hematol & Oncol, Traunstein, Germany

[8] Univ Hosp Ulm, Inst Expt Canc Res, Ulm, Germany

[9] Univ Hosp Muenster, Dept Med A Hematol Oncol & Pneumol, Munster, Germany

[10] Asklepios Klin St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[11] Charite, Med Ctr Berlin, Dept Hematol Oncol & Tumor Immunol, Campus Benjamin Franklin, Berlin, Germany

[12] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[13] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

[14] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[15] Ulm Univ, Inst Human Genet, Ulm, Germany

[16] Ulm Univ, Med Ctr, Ulm, Germany

[17] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[18] Univ Hosp Giessen, Inst Pathol Mol Cytol & Funct Genom, Giessen, Germany

[19] Julius Maximilians Univ Wurzburg, Inst Pathol, Wurzburg, Germany

[20] Univ Hosp Regensburg, Dept Nucl Med, Regensburg, Germany

[21] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[21] RANDOMIZED PHASE III STUDY OF EARLY RITUXIMAB INTENSIFICATION IN COMBINATION WITH CHOP14 FOLLOWED BY RITUXIMAB OR NO MAINTENANCE IN DIFFUSE LARGE B-CELL LYMPHOMA: A HOVON-NORDIC LYMPHOMA GROUP STUDY
Lugtenburg, P.
Brown, P. de Nully
van der Holt, B.
d'Amore, F.
Koene, H.
Berenschot, H.
Fijnheer, R.
Loosveld, O.
Bohmer, L.
Pruijt, J.
Verhoef, G.
Hoogendoorn, M.
de Kan, R.
van Imhoff, G.
van Hooije, C.
Lam, K.
de Keizer, B.
de Jong, D.
Hoekstra, O.
Zijlstra, J.
HAEMATOLOGICA, 2016, 101 : 173 - 173
[22] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Zhu, Jun
Song, Yuqin
Guo, Ye
Zhou, Keshu
Li, Wenyu
Yang, Yu
Cai, Qingqing
Wang, Zhao
Yang, Haiyan
BLOOD, 2023, 142
[23] Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study
Younes, Anas
Burke, John M.
Cheson, Bruce D.
Diefenbach, Catherine
Ferrari, Silvia
Hahn, Uwe H.
Hawkes, Eliza A.
Khan, Cyrus
Lossos, Izidore S.
Musuraca, Gerardo
Tani, Monica
Vitolo, Umberto
Yuen, Sam Lung Sang
Raval, Aparna
Shivhare, Mahesh R.
Nielsen, Tina G.
Sellam, Gila
Sharman, Jeff P.
BLOOD, 2019, 134
[24] A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
Micallef, I. N.
Maurer, M. J.
Nikcevich, D. A.
Cannon, M.
Moore, D. F., Jr.
Kurtin, P.
Witzig, T. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group
Peyrade, Frederic
Bologna, Serge
Delwail, Vincent
Emile, Jean Francois
Pascal, Laurent
Ferme, Christophe
Schiano, Jean-Marc
Coiffier, Bertrand
Corront, Bernadette
Farhat, Hassan
Fruchart, Christophe
Ghesquieres, Herve
Macro, Margaret
Tilly, Herve
Choufi, Bachra
Delarue, Richard
Fitoussi, Olivier
Gabarre, Jean
Haioun, Corinne
Jardin, Fabrice
LANCET HAEMATOLOGY, 2017, 4 (01): : E46 - E55
[26] ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
Sehn, Laurie Helen
Kahl, Brad S.
Matasar, Matthew J.
Lenz, Georg
Izutsu, Koji
Zhao, Weili
Tao, Lin
Calvo, Roser
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Davies, Andrew
Caddy, Josh
Mercer, Katy
Saunders, Geoff N.
Stanton, Louise
Collins, Graham P.
Cummin, Thomas E. C.
Schuh, Anna
Ardeshna, Kirit M.
McMillan, Andrew
Radford, John A.
Lewis, David John
Coleman, Adam
Griffiths, Gareth
Burton, Cathy
Barrans, Sharon
Johnson, Peter
BLOOD, 2020, 136
[28] Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20_ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
Rummel, M.
Kim, T. M.
Aversa, F.
Brugger, W.
Capochiani, E.
Plenteda, C.
Re, F.
Trask, P.
Osborne, S.
Smith, R.
Grigg, A.
ANNALS OF ONCOLOGY, 2017, 28 (04) : 836 - 842
[29] Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study
Wang, Yucai
Laplant, Betsy
King, Rebecca L.
Micallef, Ivana N.
Ansell, Stephen M.
Tun, Han W.
Iqbal, Madiha
Thanarajasingam, Gita
Rosenthal, Allison C.
Inwards, David J.
Johnston, Patrick B.
Porrata, Luis F.
Habermann, Thomas M.
Witzig, Thomas E.
Nowakowski, Grzegorz S.
BLOOD, 2021, 138
[30] Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303
Wilson, Wyndham H.
Sin-Ho, Jung
Pitcher, Brandelyn Nicole
Hsi, Eric D.
Friedberg, Jonathan
Cheson, Bruce
Bartlett, Nancy L.
Smith, Scott
Johnston, Nina Wagner
Kahl, Brad S.
Staudt, Louis M.
Blum, Kristie
Abramson, Jeremy
Press, Oliver W.
Fisher, Richard I.
Richards, Kristy L.
Schoder, Heiko
Chang, Julie E.
Zelenetz, Andrew D.
Leonard, John P.
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →